Stanford Medicine and MDI Health Collaborate to Advance AI-Driven Personalized Medication Management for Polypharmacy Patients

MDI Health and Stanford Medicine Collaborate on AI-Powered Medication Management Study

MDI Health, known for its personalized medication management solutions, has teamed up with Stanford Medicine’s Healthcare AI Applied Research Team (HEA₃RT) to conduct a research study on AI-driven medication analysis. This collaboration focuses on improving care for patients managing multiple chronic medications, known as polypharmacy.

Study Overview

The joint study will assess MDI Health’s Artificial Pharmacology Intelligence (API) system, which has already shown over 93% accuracy when compared to expert clinical panels. Polypharmacy affects a growing number of patients, especially as populations age, and presents significant risks including adverse drug interactions. These complications contribute to high healthcare costs—estimated at $528 billion annually in the US alone.

The research will involve reviewing about 200 patients’ medical and insurance records spanning more than a decade. Both MDI’s AI system and Stanford’s clinical pharmacists will independently generate personalized medication recommendations. A panel of senior clinical pharmacists will then evaluate the accuracy of these suggestions to ensure reliability.

Expert Insights

Dr. Janjri Desai, Executive Director of Pharmacy and HEA₃RT collaborator, highlighted the importance of this work: "Optimizing medications for complex patients is one of the most pressing challenges in healthcare. AI tools can improve efficiency for pharmacists and physicians, enhancing access to care." The study is expected to conclude in 2026, aiming to support responsible clinical integration of AI technologies.

Dr. Dorit Dil Nahlieli, Co-founder and Chief Scientist at MDI Health, emphasized the commitment to evidence-based solutions: "This collaboration deepens our focus on delivering measurable impact and accelerating AI adoption to scale personalized treatment for patients with polypharmacy."

About MDI Health

MDI Health provides an AI-driven platform that automates complex medication reviews. Its Artificial Pharmacology Intelligence system offers context-aware, evidence-based clinical insights that help healthcare professionals make safer, more informed decisions. The technology supports managing polypharmacy patients more effectively, improving outcomes while reducing costs.

For healthcare managers interested in the intersection of AI and medication management, this study represents a significant step toward scalable, personalized care solutions.